Point72 Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Point72 Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,600	Closed	-$352K	–	2520
2024 Q4	$352K	Buy	+26,600	New	+$365K	﹤0.01%	1751
2024 Q2	–	Sell	-206,100	Closed	-$2.86M	–	2427
2024 Q1	$2.86M	Buy	+206,100	New	+$3M	0.01%	1150
2023 Q3	–	Sell	-2,125,500	Closed	-$33.4M	–	2859
2023 Q2	$33.4M	Sell	2,125,500 -403,297	-16%	-$6.61M	0.1%	258
2023 Q1	$41.7M	Sell	2,528,797 -253,903	-9%	-$4.04M	0.13%	197
2022 Q4	$43.4M	Buy	+2,782,700	New	+$38.9M	0.15%	185
2021 Q4	–	Sell	-1,299,900	Closed	-$21.3M	–	1295
2021 Q3	$21.3M	Sell	1,299,900 -77,100	-6%	-$1.29M	0.09%	289
2021 Q2	$23.2M	Buy	+1,377,000	New	+$23.4M	0.1%	252
2021 Q1	–	Sell	-651,300	Closed	-$11.9M	–	1174
2020 Q4	$11.9M	Buy	+651,300	New	+$11.4M	0.06%	403
2019 Q4	–	Sell	-267,562	Closed	-$4.6M	–	1239
2019 Q3	$4.6M	Buy	+267,562	New	+$4.63M	0.03%	472
2019 Q2	–	Sell	-976,514	Closed	-$19.9M	–	1522
2019 Q1	$19.9M	Buy	+976,514	New	+$19.7M	0.09%	255

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Point72 Asset Management's TAK Position: Q1 2025 in Review

Point72 Asset Management sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 26,600 shares — an estimated $352K sold.

Point72 Asset Management first reported a position in TAK in Q1 2019 and held it in 10 quarters. The position peaked at $43.4M in Q4 2022. 307 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

Point72 Asset Management reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Point72 Asset Management sold 26,600 Takeda Pharmaceutical shares in Q1 2025, an estimated $352K.
Point72 Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 10 quarters.
Point72 Asset Management's Takeda Pharmaceutical position peaked at $43.4M in Q4 2022.
307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.